大型科技股表现 - 特斯拉股价上涨6.36%至415.960美元，涨幅领先 [2][3] - 谷歌-A股价上涨5.49%至316.120美元 [2][3] - 脸书股价上涨3.37%至614.290美元 [2][3] - 亚马逊股价上涨2.51%至226.226美元 [2][3] - 苹果股价上涨0.83%至273.740美元 [2][3] - 微软股价上涨0.60%至474.938美元 [2][3] - 英伟达股价小幅上涨0.20%至179.230美元 [2][3] 半导体行业表现 - 费城半导体指数大幅上涨3.66% [3] - 博通股价大涨9.02%至370.890美元 [5] - 美光科技股价上涨6.71%至221.290美元 [3][5] - 超威半导体股价上涨4.05%至212.025美元 [3][5] - 英特尔股价上涨3.57%至35.730美元 [3][5] - 拉姆研究股价上涨5.05%至149.860美元 [5] - 迈威尔科技股价上涨4.79%至81.160美元 [5] - COHERENT股价上涨7.28%至149.660美元 [5] 制药公司动态 - 诺和诺德股价大跌6.58%至44.495美元，盘中一度跌近10% [5][7] - 公司司美格鲁肽针对阿尔茨海默病的晚期试验未能达到目标，未将患者认知衰退速度减缓20% [5][6] - 诺和诺德市值约为1508亿美元，市盈率为8.6 [7] 中概股表现 - 纳斯达克中国金龙指数大涨2.56%至7706.31点 [9][10] - 禾赛科技股价大涨18.83%至18.335美元 [9][10] - 阿特斯太阳能股价上涨8.95%至24.655美元 [9][11] - 百度集团股价上涨7.84%至119.648美元 [9][11] - 哔哩哔哩股价上涨6.96%至26.420美元 [9][11] - 中学科工业股价大涨31.25%至3.098美元 [10] 机构市场观点 - 摩根士丹利预计标普500指数一年后将回升至7800点，较当前水平上涨约18% [11][12] - 该行对非必需消费品、医疗保健、金融、工业以及小盘股板块持乐观态度 [11] - 高盛预计美联储将在12月实施连续第三次降息，并预计2026年再降息两次，最终将联邦基金利率降至3.00%–3.25%区间 [12] - 市场预计美联储12月降息25个基点的概率升至69.5%，相比一周前的约42%明显提升 [13][14] - 纽约联储主席威廉姆斯称短期内仍有进一步降息的空间 [13]

Biogen Inc. (NASDAQ:BIIB) stock traded higher after Novo Nordisk A/S (NYSE:NVO) released disappointing topline results from the 2-year primary analysis of Evoke and Evoke+ phase 3 trials in early-stage symptomatic Alzheimer's disease.BIIB is reaching significant price levels. Watch the momentum hereThe trials did not confirm the superiority of semaglutide versus placebo in the reduction of progression of Alzheimer's disease, as measured by the change in Clinical Dementia Rating – Sum of Boxes (CDR-SB) score ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Novo Nordisk's closely-watched Alzehimer's trials - which failed on Monday to show it can slow the disease's progression - were always a long-shot, although they had offered the drugmaker a potential ... ...

Drug maker Novo Nordisk (NYSE:NVO) is sinking 7.8% to trade at $43.87 this morning, earlier hitting a more than four-year low of $43.37 after sharing disappointing trial data for its Alzheimer's drug, semaglutide. The oral medication failed to pare back progression in the memory-loss disease. NVO has been on a steep, downward trajectory since topping out at a record high of $148.15 in June of 2024. The 120-day moving average has loomed as overhead resistance, capping several breakout attempts this past year ...

编辑：雨林 11月24日，诺和诺德表示，该公司的一项口服司美格鲁肽用于治疗阿尔茨海默病的临床试验失败， 未能延缓疾病进展。诺和诺德盘前股价大跌超10%。 ...

Novo Nordisk's closely-watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the progression of the brain-wasting disease, the firm said on Monday, a blow to ... ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.ONeil Trader is a former stockbroker turned full-time independent investor. He focuses on ...

Shares of Danish pharma major Novo Nordisk's plummeted a record 12.4% on 24 November — it's lowest since July 2021, after the company's popular weight-loss pill Ozempic failed trials for Alzheimer's treatment, Bloomberg reported.Novo Nordisk has discontinued its planned one-year extension for the pair of studies that were testing the drug's effectiveness in slowing the progression of Alzheimer's disease, it added.The two trials, with 3,500 participants with mild Alzheimer’s disease, had a 75% probability of ...

诺和诺德司美格鲁肽临床试验结果 - 诺和诺德宣布其药物司美格鲁肽（semaglutide）未能延缓阿尔茨海默症的疾病进展 [1] 公司股价市场反应 - 诺和诺德股价因该负面临床试验结果而承压 [1] - 礼来（Eli Lilly）与渤健（Biogen）公司股价因相对预期提升而出现上涨 [1]